Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
- Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
- A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
- Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
- This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.